Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients

Cui, Xiaojie; Ye, Lei; Li, Jing; Jin, Ling; Wang, Wenjie; Li, Shuangyue; Bao, Minghui; Wu, Shouling; Li, Lifeng; Geng, Bin; Zhou, Xin; Zhang, Jian; Cai, Jun

doi:10.1038/s41598-017-18756-2

Cited by 232 publications

(206 citation statements)

References 68 publications

(73 reference statements)

Supporting

Mentioning

190

Contrasting

Unclassified

Order By: Relevance

“…Taken together with contemporary studies from Japan, China, and Germany, our results firmly establish that the gut microbiota is altered in patients with HF. A common finding in these studies is the relative reduction in taxa from the Lachnospiracea or Ruminococcacea family (both belonging to the Firmicutes phylum), known for their capacity of producing the short‐chain fatty acid butyrate.…”

Section: Discussionsupporting

confidence: 82%

Low fibre intake is associated with gut microbiota alterations in chronic heart failure

et al. 2020

View full text Add to dashboard Cite

Aims Recent reports have suggested that patients with heart failure (HF) have an altered gut microbiota composition; however, associations with diet remain largely uninvestigated. We aimed to explore differences in the gut microbiota between patients with HF with reduced ejection fraction and healthy controls, focusing on associations with diet and disease severity. Methods and results The microbiota composition of two cross-sectional cohorts (discovery, n = 40 and validation, n = 44) of patients with systolic HF and healthy controls (n = 266) was characterized by sequencing of the bacterial 16S rRNA gene. The overall microbial community (beta diversity) differed between patients with HF and healthy controls in both cohorts (P < 0.05). Patients with HF had shifts in the major bacterial phyla, resulting in a lower Firmicutes/Bacteroidetes (F/B) ratio than controls (P = 0.005). Patients reaching a clinical endpoint (listing for heart transplant or death) had lower bacterial richness and lower F/B ratio than controls (P < 0.01). Circulating levels of trimethylamine-N-oxide were associated with meat intake (P = 0.016), but not with gut microbiota alterations in HF. Low bacterial richness and low abundance of several genera in the Firmicutes phylum were associated with low fibre intake. Conclusions The gut microbiota in HF was characterized by decreased F/B ratio and reduced bacterial diversity associated with clinical outcome. The gut microbiota alterations in HF were partly related to low fibre intake, emphasizing the importance of diet as a covariate in future studies. Our data could provide a rationale for targeting the gut microbiota in HF with high-fibre diet.

show abstract

Section: Discussionsupporting

confidence: 82%

Low fibre intake is associated with gut microbiota alterations in chronic heart failure

et al. 2020

View full text Add to dashboard Cite

show abstract

“…With the establishment of the heart‐gut axis concept, accumulating studies have suggested that the gut microbiome plays an important role in the genesis of cardiovascular diseases, including HTN. Our previous study depicted the signature of dysbiotic GM in HTN patients and demonstrated the causal relationship between GM dysbiosis and HTN . As the understanding of the relationship between intestinal microbiome and diseases has deepened, possible underlying mechanisms have been proposed.…”

Section: Discussionmentioning

confidence: 93%

Dysbiotic gut microbes may contribute to hypertension by limiting vitamin D production

Zuo

et al. 2019

Clinical Cardiology

Self Cite

View full text Add to dashboard Cite

Background Accumulating studies have suggested that gut microbiota (GM) dysbiosis and vitamin D3 deficiency each play an important role during the progression of hypertension (HTN). However, few studies have characterized the underlying interaction between GM shift and vitamin D3 deficiency in HTN patients. Hypothesis This study aimed to evaluate the possible crosstalk between GM dysbiosis and vitamin D deficiency in the pathogenesis of HTN. Methods In a cohort of 34 HTN patients and 15 healthy controls, we analyzed the fecal microbiota products, GM composition, and the interaction between GM and vitamin D3. Results Vitamin D3 was significantly decreased in feces of HTN patients (P = .006, vs controls) and was correlated with altered GM, including decreased Shannon index (R2 = 0.1296, P = .0111) and Pielou evenness (R2 = 0.1509, P = .0058). Moreover, vitamin D3 positively correlated with HTN‐reduced bacterial genera, including Subdoligranulum (R2 = 0.181, P = .0023), Ruminiclostridium (R2 = 0.1217, P = .014), Intestinimonas (R2 = 0.2036, P = .0011), Pseudoflavonifractor (R2 = 0.1014, P = .0257), Paenibacillus (R2 = 0.089, P = .0373), and Marvinbryantia (R2 = 0.08173, P = .0464). Partial least squares structural equation modeling showed that 27.7% of the total effect of gut microbiome on HTN was mediated by limiting vitamin D production. Finally, receiver operating characteristic curve analysis revealed the predictive capacity of differential gut microbiome signatures and decreased vitamin D3 to distinguish HTN patients (AUC = 0.749, P = .006). Conclusions Our findings suggest that the GM dysbiosis contributing to the development of HTN might be partially mediated by vitamin D3 deficiency. Future studies involving the underlying mechanism and intervention strategies targeting microbiome composition and vitamin D3 to counteract the progression of HTN are warranted.

show abstract

“…intestinal inflammation associated with changes in the underlying mesenteric fat depots as venular dilatation and congestion, and perivascular accumulation of neutrophils [256]. Systemic congestive phenomena due to heart failure associated with distinct gut microbiota dysbiosis [257].…”

Section: Muscle Aging and Gut Microbiotamentioning

confidence: 99%

Towards Individualized Use of Probiotics and Prebiotics for Metabolic Syndrome and Associated Diseases Treatment: Does Pathophysiology-Based Approach Work and Can Anticipated Evidence Be Completed?

Bubnov¹,

Spivak²

2018

Preprint

View full text Add to dashboard Cite

The modification the gut microbiota in metabolic syndrome and associated chronic diseases is among leading tasks of microbiome research and needs for clinical use of probiotics. Evidence lack for the implications for microbiome modification to improve metabolic health in particular when applied impersonalized. Probiotics have tremendous potential in personalized nutrition and medicine to develop healthy diets. The aim was to to conduct comprehensive overview of recent updates of role of microbiota on human health and development of metabolic syndrome and efficacy of microbiota modulation considering specific properties of probiotic strain and particular aspects of metabolic syndrome and patient`s phenotype to fill the gap between probiotic product and individual to facilitate development of individualized / personalized probiotic and prebiotic treatments. We discuss the relevance of using host phenotype-associated biomarkers, those based on imaging and molecular and patrient`s history, reliable and accessible to facilitate person-specific appication of probiotics and prebiotic substances. Microbiome phenotypes can be parameters of predictive medicine to recognize patient`s predispositions and evaluate treatment responses; the number of phenotype markers can be effectively involved to monitor microbiome modulation. The studied strain-dependent properties of probiotic strains are potentially relevant for individualized treatment for gut and distant sites microbiome modulation. The evidence regarding probiotic strains properties can be taken to account via pathophysiology-based approach for most effective individualized treatment via gut, oral and vaginal and other sites microbiome modulation according to phenotype of the patient providing individualized and personalized medical approaches. Preventive potential of probiotics is strong and well-documented. Recommendations for individualized clinical use of probiotics, and for probiotic studies design have been suggested.

show abstract

Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients

Cited by 232 publications

References 68 publications

Low fibre intake is associated with gut microbiota alterations in chronic heart failure

Low fibre intake is associated with gut microbiota alterations in chronic heart failure

Dysbiotic gut microbes may contribute to hypertension by limiting vitamin D production

Towards Individualized Use of Probiotics and Prebiotics for Metabolic Syndrome and Associated Diseases Treatment: Does Pathophysiology-Based Approach Work and Can Anticipated Evidence Be Completed?

Contact Info

Product

Resources

About